Chaewon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chaewon Park has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Tae Hyun Kim
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea
2 shared publications - Chang-Young Jang
Muscle Physiome Research Center, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sookmyung Women’s University, Seoul 04310, Republic of Korea
1 shared publication - Hwamok Oh
Muscle Physiome Research Center, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sookmyung Women’s University, Seoul 04310, Republic of Korea
1 shared publication - Hyejin Kim
College of pharmacy, Sookmyung Women’s University, Seoul 04310, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1410
Context-Dependent Redox Mechanisms in Drug-Induced Liver Injury: Shared and Distinct Roles Across Hepatocellular and Cholestatic Phenotypes
Oxidative stress and redox dysregulation are widely implicated in drug-induced liver injury (DILI), yet their roles vary considerably according to the initiating insult, cellular context, and stage of injury. Rather than representing a single pathogenic mechanism, redox disturbances may function as initiating contributors, injury amplifiers, adaptive responses, or downstream consequences of tissue injury. This review examines these context-dependent roles using hepatocellular and cholestatic DILI as complementary settings for distinguishing shared and divergent redox mechanisms. We discuss how mitochondrial oxidant stress, glutathione- and thioredoxin-dependent defenses, nuclear factor erythroid 2-related factor 2 (NRF2)-mediated adaptation, redox-sensitive signaling, lipid peroxidation, and inflammatory oxidants occupy different positions within the injury cascade across representative DILI settings. This review focuses particularly on the sources, spatial organization, timing, molecular targets, and consequences of redox events, all of which are considered together with their magnitude. This perspective may help reconcile apparently inconsistent findings across experimental models and improve the mechanistic interpretation of redox biomarkers and therapeutic interventions in DILI.
- 1 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (11) , 1410
Open AccessContext-Dependent Redox Mechanisms in Drug-Induced Liver Injury: Shared and Distinct Roles Across Hepatocellular and Cholestatic Phenotypes
Oxidative stress and redox dysregulation are widely implicated in drug-induced liver injury (DILI), yet their roles vary considerably according to the initiating insult, cellular context, and stage of injury. Rather than representing a single pathogenic mechanism, redox disturbances may function as initiating contributors, injury amplifiers, adaptive responses, or downstream consequences of tissue injury. This review examines these context-dependent roles using hepatocellular and cholestatic DILI as complementary settings for distinguishing shared and divergent redox mechanisms. We discuss how mitochondrial oxidant stress, glutathione- and thioredoxin-dependent defenses, nuclear factor erythroid 2-related factor 2 (NRF2)-mediated adaptation, redox-sensitive signaling, lipid peroxidation, and inflammatory oxidants occupy different positions within the injury cascade across representative DILI settings. This review focuses particularly on the sources, spatial organization, timing, molecular targets, and consequences of redox events, all of which are considered together with their magnitude. This perspective may help reconcile apparently inconsistent findings across experimental models and improve the mechanistic interpretation of redox biomarkers and therapeutic interventions in DILI.
- Open Access
Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) refers to a range of conditions in which excess lipids accumulate in the liver, possibly leading to serious hepatic manifestations such as steatohepatitis, fibrosis/cirrhosis and cancer. Despite its increasing prevalence and significant impact on liver disease-associated mortality worldwide, no medication has been approved for the treatment of NAFLD yet. Liver X receptors α/β (LXRα and LXRβ) are lipid-activated nuclear receptors that serve as master regulators of lipid homeostasis and play pivotal roles in controlling various metabolic processes, including lipid metabolism, inflammation and immune response. Of note, NAFLD progression is characterized by increased accumulation of triglycerides and cholesterol, hepatic de novo lipogenesis, mitochondrial dysfunction and augmented inflammation, all of which are highly attributed to dysregulated LXR signaling. Thus, targeting LXRs may provide promising strategies for the treatment of NAFLD. However, emerging evidence has revealed that modulating the activity of LXRs has various metabolic consequences, as the main functions of LXRs can distinctively vary in a cell type-dependent manner. Therefore, understanding how LXRs in the liver integrate various signaling pathways and regulate metabolic homeostasis from a cellular perspective using recent advances in research may provide new insights into therapeutic strategies for NAFLD and associated metabolic diseases.
Open AccessTargeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) refers to a range of conditions in which excess lipids accumulate in the liver, possibly leading to serious hepatic manifestations such as steatohepatitis, fibrosis/cirrhosis and cancer. Despite its increasing prevalence and significant impact on liver disease-associated mortality worldwide, no medication has been approved for the treatment of NAFLD yet. Liver X receptors α/β (LXRα and LXRβ) are lipid-activated nuclear receptors that serve as master regulators of lipid homeostasis and play pivotal roles in controlling various metabolic processes, including lipid metabolism, inflammation and immune response. Of note, NAFLD progression is characterized by increased accumulation of triglycerides and cholesterol, hepatic de novo lipogenesis, mitochondrial dysfunction and augmented inflammation, all of which are highly attributed to dysregulated LXR signaling. Thus, targeting LXRs may provide promising strategies for the treatment of NAFLD. However, emerging evidence has revealed that modulating the activity of LXRs has various metabolic consequences, as the main functions of LXRs can distinctively vary in a cell type-dependent manner. Therefore, understanding how LXRs in the liver integrate various signaling pathways and regulate metabolic homeostasis from a cellular perspective using recent advances in research may provide new insights into therapeutic strategies for NAFLD and associated metabolic diseases.